Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ERAS NASDAQ:OVID NASDAQ:PEPG On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeERASErasca$10.23-1.4%$15.23$1.06▼$24.28$3.18B0.689.87 million shs3.33 million shsOVIDOvid Therapeutics$2.63-6.1%$2.50$0.27▼$3.11$346.83M0.182.07 million shs1.25 million shsPEPGPepGen$1.55-6.1%$2.96$1.01▼$7.80$107.21M2.01932,882 shs716,347 shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceERASErasca0.00%+1.09%-43.88%-14.75%+705.51%OVIDOvid Therapeutics0.00%-6.07%-6.07%+85.21%+791.83%PEPGPepGen0.00%-11.93%-7.19%-75.93%+12.32%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeERASErasca$10.23-1.4%$15.23$1.06▼$24.28$3.18B0.689.87 million shs3.33 million shsOVIDOvid Therapeutics$2.63-6.1%$2.50$0.27▼$3.11$346.83M0.182.07 million shs1.25 million shsPEPGPepGen$1.55-6.1%$2.96$1.01▼$7.80$107.21M2.01932,882 shs716,347 shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceERASErasca0.00%+1.09%-43.88%-14.75%+705.51%OVIDOvid Therapeutics0.00%-6.07%-6.07%+85.21%+791.83%PEPGPepGen0.00%-11.93%-7.19%-75.93%+12.32%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceERASErasca 2.50Moderate Buy$18.7583.28% UpsideOVIDOvid Therapeutics 2.89Moderate Buy$5.1394.87% UpsidePEPGPepGen 2.67Moderate Buy$11.60648.39% UpsideCurrent Analyst Ratings BreakdownLatest PEPG, OVID, and ERAS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/14/2026OVIDOvid Therapeutics Roth MkmSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$7.005/13/2026PEPGPepGen WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$5.00 ➝ $4.005/12/2026ERASErasca MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$28.00 ➝ $26.004/27/2026ERASErasca Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$20.00 ➝ $30.004/21/2026OVIDOvid Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/21/2026PEPGPepGen Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/15/2026OVIDOvid Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$7.004/9/2026OVIDOvid Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$2.00 ➝ $4.003/31/2026PEPGPepGen WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$9.00 ➝ $5.003/26/2026OVIDOvid Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$4.003/20/2026OVIDOvid Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$5.00 ➝ $7.00(Data available from 5/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookERASErascaN/AN/AN/AN/A$1.27 per shareN/AOVIDOvid Therapeutics$7.12M48.70N/AN/A$1.50 per share1.75PEPGPepGenN/AN/AN/AN/A$1.94 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateERASErasca-$124.55M-$0.93N/AN/AN/AN/A-35.31%-29.49%N/AOVIDOvid Therapeutics-$17.41M-$0.29N/AN/AN/A-240.11%-22.51%-18.67%N/APEPGPepGen-$89.65M-$1.75N/AN/AN/AN/A-59.89%-49.62%N/ALatest PEPG, OVID, and ERAS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q1 2026OVIDOvid Therapeutics-$0.12-$0.12N/A-$0.12$0.06 millionN/A5/12/2026Q1 2026PEPGPepGen-$0.31-$0.26+$0.05-$0.26N/AN/A5/11/2026Q1 2026ERASErasca-$0.1150-$0.60-$0.4850-$0.60N/AN/A3/18/2026Q4 2025OVIDOvid Therapeutics-$0.10$0.06+$0.16$0.06$0.06 million$0.72 million3/12/2026Q4 2025ERASErasca-$0.11-$0.10+$0.01-$0.10N/AN/A3/4/2026Q4 2025PEPGPepGen-$0.40-$0.27+$0.13-$0.27N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthERASErascaN/AN/AN/AN/AN/AOVIDOvid TherapeuticsN/AN/AN/AN/AN/APEPGPepGenN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioERASErascaN/A9.5210.04OVIDOvid Therapeutics0.0610.178.97PEPGPepGenN/A14.9811.94Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipERASErasca67.78%OVIDOvid Therapeutics72.24%PEPGPepGen58.01%Insider OwnershipCompanyInsider OwnershipERASErasca14.20%OVIDOvid Therapeutics13.10%PEPGPepGen1.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableERASErasca120310.98 million266.83 millionOptionableOVIDOvid Therapeutics60131.88 million114.60 millionOptionablePEPGPepGen3069.17 million68.27 millionNot OptionablePEPG, OVID, and ERAS HeadlinesRecent News About These CompaniesPepGen (PEPG) Upgraded to Buy: Here's What You Should KnowMay 13, 2026 | zacks.comPepGen Reports First Quarter 2026 Financial Results and Recent Corporate HighlightsMay 12, 2026 | businesswire.comPepGen, Inc. (NASDAQ:PEPG) Given Average Recommendation of "Moderate Buy" by BrokeragesMay 8, 2026 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPGMay 7, 2026 | prnewswire.comPepGen (PEPG) Projected to Post Earnings on ThursdayMay 7, 2026 | marketbeat.comPictet Asset Management Holding SA Purchases 871,059 Shares of PepGen, Inc. $PEPGMay 3, 2026 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPGApril 30, 2026 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPGApril 28, 2026 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: PepGen Inc. (PEPG) and IDEAYA Biosciences (IDYA)April 26, 2026 | theglobeandmail.comStifel Nicolaus Sticks to Its Buy Rating for PepGen Inc. (PEPG)April 26, 2026 | theglobeandmail.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPGApril 21, 2026 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPGApril 16, 2026 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPGApril 14, 2026 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPGApril 9, 2026 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPGApril 7, 2026 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPGApril 2, 2026 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPGApril 2, 2026 | prnewswire.comPepGen Plunges On Mixed Phase 2 Data, But Higher Dose Could Offer Some ReliefMarch 31, 2026 | seekingalpha.comPepGen Loses Half of Share Price on Mixed Data in Rare Muscle-Wasting DiseaseMarch 31, 2026 | biospace.comBINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPGMarch 31, 2026 | globenewswire.comPepGen Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their LossesMarch 31, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines3 Space ETFs to Pick Up Before SpaceX IPOBy Nathan Reiff | April 19, 2026Is Oracle Undervalued as Cloud Growth Accelerates?By Thomas Hughes | April 29, 2026Is Backblaze the Next Momentum Monster?By Jeffrey Neal Johnson | May 7, 2026More Than Just Dirt: Caterpillar Is the AI Stock Nobody Saw ComingBy Jeffrey Neal Johnson | April 23, 2026Legence Stock Up 185% Since IPO—Could 50% Upside Lie Ahead?By Thomas Hughes | April 23, 2026PEPG, OVID, and ERAS Company DescriptionsErasca NASDAQ:ERAS$10.23 -0.14 (-1.35%) Closing price 05/15/2026 04:00 PM EasternExtended Trading$10.24 +0.00 (+0.05%) As of 05/15/2026 07:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.Ovid Therapeutics NASDAQ:OVID$2.63 -0.17 (-6.07%) Closing price 05/15/2026 04:00 PM EasternExtended Trading$2.65 +0.02 (+0.76%) As of 05/15/2026 07:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.PepGen NASDAQ:PEPG$1.55 -0.10 (-6.06%) Closing price 05/15/2026 04:00 PM EasternExtended Trading$1.59 +0.04 (+2.65%) As of 05/15/2026 07:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients. The company is also developing PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 1 clinical trial for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. PepGen Inc. was founded in 2018 and is based in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Peloton Stock Gives Back Gains After Upbeat Earnings Report MarketBeat Week in Review – 05/11 - 05/15 Datavalut Gains Traction: 5 Reasons to Sell Now TMC Stock: Why This Pre-Revenue Miner Is Worth Watching Alphabet's Googlebook Brings Gemini AI to PC Hardware As Broadcom Eclipses $2 Trillion, Private Credit Giants Wants In Robinhood, SoFi, and Webull Are Telling Very Different Stories Viking Sails to All-Time Highs—Fundamentals Signal More to Come Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
